Search research articles
Contact Us
Filters
Showing results (61-70 of 102) with videos related to
Page
of 11
Sort By:
The Journal of Clinical Investigation
|
October 25, 2016
MicroRNA-29b mediates altered innate immune development in acute leukemia
Bethany L Mundy-Bosse, Steven D Scoville, Li Chen, et al.
American Journal of Hematology
|
August 11, 2020
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
Caner Saygin, Karilyn Larkin, James S Blachly, et al.
Blood Advances
|
July 12, 2018
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission
Sumithira Vasu, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
Blood
|
March 26, 2016
Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts
Sumithira Vasu, Shun He, Carolyn Cheney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2021
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome
Ryotaro Nakamura, Wael Saber, Michael J Martens, et al.
Cancers
|
February 9, 2021
Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
Nidhi Sharma, Qiuhong Zhao, Bin Ni, et al.
Transplantation and Cellular Therapy
|
April 7, 2022
Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012
Claudio G Brunstein, Paul V O'Donnell, Brent Logan, et al.
Blood
|
March 19, 2025
Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
Zachariah DeFilipp, Haesook T Kim, Laura W Knight, et al.
Transplantation and Cellular Therapy
|
June 13, 2025
An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy: Consensus Response Criteria for TA-TMA
Michelle L Schoettler, Eleni Gavriilaki, Enric Carreras, et al.
Haematologica
|
March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485
Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 102) with videos related to
Sort By:
Page
of 11
The Journal of Clinical Investigation
|
October 25, 2016
MicroRNA-29b mediates altered innate immune development in acute leukemia
Bethany L Mundy-Bosse, Steven D Scoville, Li Chen, et al.
American Journal of Hematology
|
August 11, 2020
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
Caner Saygin, Karilyn Larkin, James S Blachly, et al.
Blood Advances
|
July 12, 2018
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission
Sumithira Vasu, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
Blood
|
March 26, 2016
Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts
Sumithira Vasu, Shun He, Carolyn Cheney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2021
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome
Ryotaro Nakamura, Wael Saber, Michael J Martens, et al.
Cancers
|
February 9, 2021
Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
Nidhi Sharma, Qiuhong Zhao, Bin Ni, et al.
Transplantation and Cellular Therapy
|
April 7, 2022
Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012
Claudio G Brunstein, Paul V O'Donnell, Brent Logan, et al.
Blood
|
March 19, 2025
Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
Zachariah DeFilipp, Haesook T Kim, Laura W Knight, et al.
Transplantation and Cellular Therapy
|
June 13, 2025
An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy: Consensus Response Criteria for TA-TMA
Michelle L Schoettler, Eleni Gavriilaki, Enric Carreras, et al.
Haematologica
|
March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485
Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Page
of 11